Literature DB >> 27717584

Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.

Roman Tatura1, Theo Kraus2, Armin Giese2, Thomas Arzberger3, Malte Buchholz4, Günter Höglinger5, Ulrich Müller6.   

Abstract

INTRODUCTION: In order to better understand the role of epigenetic influences in the etiology of Parkinson's disease (PD), we studied the expression of microRNAs in gyri cinguli of patients and controls.
METHODS: Expression profiling of 744 well-characterized microRNAs in gyri cinguli from patients and controls using TaqMan array microRNA cards. Verification of significantly dysregulated microRNAs by SYBR Green qRT-PCR.
RESULTS: First screen by TaqMan array identified 43 microRNAs that were upregulated in gyri cinguli from patients. Of those microRNAs, 13 are predicted to regulate at least one of six genes mutated in monogenic forms of PD (DJ-1, PARK2, PINK1, LRRK2, SNCA, and HTRA2). Five of these 13 microRNAs (-144, -199b, -221, -488, -544) were also found upregulated by SYBR Green qRT-PCR and are predicted to regulate either SNCA, PARK2, LRRK2 or combinations thereof. Consistently, expression of SNCA, PARK2, and LRRK2 was reduced in patients. An additional 5 out of ten potential target genes tested were downregulated. These are DRAM (DNA damage regulated autophagy modulator 1), predicted to be regulated by miR-144, EVC (Ellis Van Creveld Protein) by miR-221, ZNF440 (Zinc Finger Protein 440) by miR-199b, MTFMT (Mitochondrial Methionyl-tRNA Formyltransferase) by miR-488 and XIRP2 (Xin Actin Binding Repeat Containing) possibly controlled by miR-544a.
CONCLUSION: The study identified five microRNAs that play a role in the etiology of Parkinson's disease likely by modifying expression of SNCA, PARK2, LRRK2 and additional genes required for normal cellular function.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  LRRK2; PARK2; Parkinson's disease; SNCA; TaqMan; miR-144; miR-199b; miR-221; miR-488; miR-544

Mesh:

Substances:

Year:  2016        PMID: 27717584     DOI: 10.1016/j.parkreldis.2016.09.028

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  22 in total

Review 1.  MicroRNAs in Parkinson's disease.

Authors:  Abhishek Singh; Dwaipayan Sen
Journal:  Exp Brain Res       Date:  2017-05-19       Impact factor: 1.972

2.  Brain pathway differences between Parkinson's disease patients with and without REM sleep behavior disorder.

Authors:  Mina Ansari; Farzaneh Rahmani; Mahsa Dolatshahi; Atefe Pooyan; Mohammad Hadi Aarabi
Journal:  Sleep Breath       Date:  2016-11-16       Impact factor: 2.816

Review 3.  Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Authors:  Masayuki Nakamori; Eunsung Junn; Hideki Mochizuki; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 4.  MicroRNAs in the pathophysiology of Alzheimer's disease and Parkinson's disease: an overview.

Authors:  Mohammad Rafi Khezri; Keyvan Yousefi; Naime Majidi Zolbanin; Morteza Ghasemnejad-Berenji
Journal:  Mol Neurobiol       Date:  2022-01-09       Impact factor: 5.590

5.  Identification of Altered Blood MicroRNAs and Plasma Proteins in a Rat Model of Parkinson's Disease.

Authors:  Sanjeev Kumar Yadav; Anuj Pandey; Sana Sarkar; Smriti Singh Yadav; Devendra Parmar; Sanjay Yadav
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.590

Review 6.  MicroRNAs in Parkinson's disease and emerging therapeutic targets.

Authors:  Bridget Martinez; Philip V Peplow
Journal:  Neural Regen Res       Date:  2017-12       Impact factor: 5.135

7.  Alpha-synuclein mRNA isoform formation and translation affected by polymorphism in the human SNCA 3'UTR.

Authors:  Elizabeth S Barrie; Sung-Ha Lee; John T Frater; Maria Kataki; Douglas W Scharre; Wolfgang Sadee
Journal:  Mol Genet Genomic Med       Date:  2018-05-06       Impact factor: 2.183

8.  Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation.

Authors:  Sylvia Torres-Odio; Jana Key; Hans-Hermann Hoepken; Júlia Canet-Pons; Lucie Valek; Bastian Roller; Michael Walter; Blas Morales-Gordo; David Meierhofer; Patrick N Harter; Michel Mittelbronn; Irmgard Tegeder; Suzana Gispert; Georg Auburger
Journal:  J Neuroinflammation       Date:  2017-08-02       Impact factor: 8.322

Review 9.  MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease.

Authors:  Ahmad R Arshad; Siti A Sulaiman; Amalia A Saperi; Rahman Jamal; Norlinah Mohamed Ibrahim; Nor Azian Abdul Murad
Journal:  Front Mol Neurosci       Date:  2017-10-31       Impact factor: 5.639

10.  The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress.

Authors:  Stephanie E Oh; Hye-Jin Park; Liqiang He; Catherine Skibiel; Eunsung Junn; M Maral Mouradian
Journal:  Redox Biol       Date:  2018-08-03       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.